Proteome Sciences (PRM) Trading Up 2.9%

Proteome Sciences plc (LON:PRM) was up 2.9% during trading on Wednesday . The stock traded as high as GBX 3.93 ($0.05) and last traded at GBX 3.50 ($0.05). Approximately 795,573 shares were traded during mid-day trading, an increase of 797% from the average daily volume of 88,695 shares. The stock had previously closed at GBX 3.40 ($0.04).

Separately, FinnCap reiterated a “corporate” rating on shares of Proteome Sciences in a research note on Tuesday.

In related news, insider Martin Diggle purchased 500,000 shares of the firm’s stock in a transaction dated Monday, August 13th. The stock was bought at an average price of GBX 4 ($0.05) per share, for a total transaction of £20,000 ($26,133.54).

COPYRIGHT VIOLATION NOTICE: This article was originally published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at

Proteome Sciences Company Profile (LON:PRM)

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. It delivers content for personalized medicine in the areas of biomarker services, biomarker assays, isobaric and isotopic reagents, and proprietary biomarkers. The company designs, performs, and interprets high resolution proteomics studies to improve target discovery, validation, and mechanism of action studies; offers specialized services to enhance discovery and validation of mechanistic biomarkers in peripheral fluids; and provides a set of bioinformatics tools to enhance data integration, and select regulated features and map to biological processes.

Further Reading: The risks of owning bonds

Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with's FREE daily email newsletter.

Leave a Reply